The DSC2 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the DSC2 gene in human renal carcinoma cells. This heterogeneous pool contains a range of CRISPR/Cas9-mediated gene disruptions, generated without single-cell cloning, thus minimizing clonal selection bias and providing a robust model to investigate desmosomal cadherin function in a population-based context.
The host 786-O line is a human clear cell renal cell carcinoma (ccRCC) line with a mutation in the von Hippel-Lindau (VHL) tumor suppressor gene, leading to constitutive stabilization of hypoxia-inducible factors (HIFs) and downstream angiogenic and metabolic reprogramming. This VHL-deficient background is widely used to study kidney cancer mechanisms, offering a genetically defined context to examine how loss of adhesion molecules like DSC2 contributes to tumor progression and metastasis.
DSC2 encodes desmocollin-2, a calcium-dependent cadherin that is an essential component of desmosomal cell-cell junctions. It is regulated upstream by Wnt ligands, the p63 transcription factor, calcium influx, and protein kinase C (PKC) signaling. Within the desmosomal plaque, DSC2 interacts directly with armadillo proteins plakoglobin (JUP) and plakophilin (PKP), which couple to the plakin family member desmoplakin (DSP), anchoring the junction to keratin intermediate filaments. Disruption of DSC2 compromises desmosomal integrity, leading to altered downstream signaling through plakoglobin and desmoplakin, which in turn affects cytoskeletal reorganization, cell adhesion strength, and suppression of cell migration.
In the 786-O ccRCC context, DSC2 knockout is expected to weaken desmosomal adhesion, potentially promoting epithelial-mesenchymal transition (EMT) and enhancing migratory and invasive behavior. This engineered model allows researchers to dissect how desmosomal protein loss cooperates with VHL mutation to drive aggressive tumor phenotypes. The DSC2 polyclonal knockout cells are thus a valuable tool for investigating the interplay between cell adhesion defects and oncogenic signaling cascades specifically in renal carcinoma.
These cells are amenable to a variety of phenotypic assays, including Western blotting and immunofluorescence for assessing expression and localization of desmosomal components such as desmoplakin and plakoglobin, Boyden chamber migration and invasion assays to quantify metastatic potential, and hanging drop or aggregation assays to measure calcium-dependent adhesion. Transcriptomic analysis by RNA-seq can reveal global gene expression changes and pathway alterations upon DSC2 knockout. These applications facilitate studies on desmosome biology, therapeutic targeting of cell adhesion molecules, and the role of DSC2 in cancer metastasis. For further information, please contact Ascent Research.
